Predictive Value of PIIINP and Urinary NGAL in Renal Function Recovery
NCT02889575
Acute Kidney Injury, Acute Kidney Tubular Necrosis
Nantes, France
View Trial DetailsNCT Number: NCT00659724
The purpose of this study is to collect information on the ease of use and thrombogenicity of the Polyflux HD-C4 Big and Fresenius Optiflux 180NR or 200NR dialyzers under conditions of routine clinical use for hemodialysis.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Advanced Dialysis Center of Easton, Easton, Maryland, United States
This ease of use study involves the use of FDA 510(k) cleared hemodialyzers and will have no impact on the patient's routine dialysis therapy. This study is aimed at obtaining feedback from the nursing and technical staff regarding the use and thrombogenicity of the Polyflux HD-C4 Big, and Fresenius Optiflux 180NR or 200NR dialyzers. The dialysis nursing staff will complete ease of use and thrombogenicity assessments following routine dialysis therapy. Any adverse events will be tracked for the study patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Priming at each treatment
For every study treatment/dialyzer, the nursing staff rated the ease of priming blood side as follows:
Very Easy:Air is easily removed without knocking or clamping procedures. Acceptable:Knocking and/or clamping required for efficient air removal. Difficult:Knocking and/or clamping and additional volume of saline or extended recirculation needed to remove air.
Very Difficult:Air could not be removed.
Time frame: Priming at each treatment
For every study treatment/dialyzer, the nursing staff rated the ease of priming dialysate side as follows:
Dialysate Side at 500 ml Priming Volume (check one):
Perfect: No air visible. Acceptable: Some air visible, but considered insignificant. Not Acceptable: Additional actions needed to sufficiently remove air.
Time frame: Each treatment: assessment of the condition of the dialyzer fibers after rinse-back
For every study treatment/dialyzer, the nursing staff rated the condition of the dialyzer fibers after rinse-back as follows:
Very Good:All fibers appear white. Good:Few fibers (less than 10) appear PINK / RED. (check one) Poor:Several fibers (more than 10) appear PINK / RED. (check one) Very Poor:Most fibers (more than 75%) appear PINK / RED. (check one)
Time frame: Each treatment: assessment of the condition of the arterial header after rinse-back
For every study treatment/dialyzer, the nursing staff rated the condition of the arterial header after rinse-back as follows:
Very Good:Surface as clean as expected. Good:Distinct red ring appears at the dialyzer wall. Poor:Significant appearance of clots, randomly distributed on the surface. Very Poor:Completely red and/or covered with clots.
Time frame: Each treatment: the assessment of the condition of the venous header after rinse-back
For every study treatment/dialyzer, the nursing staff rated the condition of the venous header after rinse-back as follows:
Very Good:Surface as clean as expected. Good:Distinct red ring appears at the dialyzer wall. Poor:Significant appearance of clots, randomly distributed on the surface. Very Poor:Completely red and/or covered with clots.
Vantive Health LLC
Industry
The Gambro Polyflux HD-C4 Big Ease Of Use And Thrombogenicity Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02889575
Acute Kidney Injury, Acute Kidney Tubular Necrosis
Nantes, France
View Trial DetailsNCT06216015
Chronic Disease, Chronic Kidney Failure
View Trial DetailsNCT07545629
Chronic Disease, Chronic Kidney Disease, Stage IV (Severe)
Wuhu, Anhui, China
View Trial DetailsNCT01845402
Cardiovascular Abnormalities, Cardiovascular Diseases
Paris, France
View Trial Details